---
title: "Acurx Pharmaceuticals (ACXP) Gets a Buy from Alliance Global Partners"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/279081167.md"
description: "Acurx Pharmaceuticals (ACXP) has received a Buy rating from Alliance Global Partners, with a price target of $10.00, as reported by James Molloy. Molloy, who covers the Healthcare sector, has an average return of -25.0% and a 19.00% success rate on his recommendations. Additionally, H.C. Wainwright's Matthew Keller also issued a Buy rating for Acurx today, while TipRanks – DeepSeek maintained a Hold rating on the stock."
datetime: "2026-03-13T17:35:36.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/279081167.md)
  - [en](https://longbridge.com/en/news/279081167.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/279081167.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/279081167.md) | [繁體中文](https://longbridge.com/zh-HK/news/279081167.md)


# Acurx Pharmaceuticals (ACXP) Gets a Buy from Alliance Global Partners

In a report released today, James Molloy from Alliance Global Partners reiterated a Buy rating on Acurx Pharmaceuticals, with a price target of $10.00.

### Claim 70% Off TipRanks Premium

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

Molloy covers the Healthcare sector, focusing on stocks such as Pelthos Therapeutics, Tonix Pharma, and Soligenix. According to TipRanks, Molloy has an average return of \-25.0% and a 19.00% success rate on recommended stocks.

In addition to Alliance Global Partners, Acurx Pharmaceuticals also received a Buy from H.C. Wainwright’s Matthew Keller in a report issued today. However, on the same day, TipRanks – DeepSeek reiterated a Hold rating on Acurx Pharmaceuticals (NASDAQ: ACXP).

### Related Stocks

- [First Trust NYSE Arca Biotech ETF (FBT.US)](https://longbridge.com/en/quote/FBT.US.md)
- [State Street® SPDR® S&P® Biotech ETF (XBI.US)](https://longbridge.com/en/quote/XBI.US.md)
- [Direxion Daily S&P Biotech Bull 3X ETF (LABU.US)](https://longbridge.com/en/quote/LABU.US.md)
- [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/en/quote/IBB.US.md)
- [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/en/quote/PBE.US.md)
- [ALPS Medical Breakthroughs ETF (SBIO.US)](https://longbridge.com/en/quote/SBIO.US.md)
- [Acurx Pharmaceuticals, Inc. (ACXP.US)](https://longbridge.com/en/quote/ACXP.US.md)
- [iShares US Pharmaceuticals ETF (IHE.US)](https://longbridge.com/en/quote/IHE.US.md)
- [State Street®HlthCrSelSectSPDR®ETF (XLV.US)](https://longbridge.com/en/quote/XLV.US.md)
- [VanEck Biotech ETF (BBH.US)](https://longbridge.com/en/quote/BBH.US.md)
- [ProShares Ultra Nasdaq Biotechnology (BIB.US)](https://longbridge.com/en/quote/BIB.US.md)
- [ARK Genomic Revolution ETF (ARKG.US)](https://longbridge.com/en/quote/ARKG.US.md)
- [Vanguard Health Care ETF (VHT.US)](https://longbridge.com/en/quote/VHT.US.md)

## Related News & Research

- [Chardan Capital Issues a Buy Rating on Solid Biosciences (SLDB)](https://longbridge.com/en/news/278782194.md)
- [Acurx Advances Ibezapolstat Program for Recurrent C. difficile](https://longbridge.com/en/news/278399773.md)
- [Solid Biosciences: Strengthened Dystrophin Data and Emerging Cardiac Benefits Support Buy Rating on SGT-003](https://longbridge.com/en/news/278770627.md)
- [Acurx Pharmaceuticals Q4 net loss narrows on lower R&D spend](https://longbridge.com/en/news/279032442.md)
- [Incannex Healthcare Prices $10 Mln Potential Offering Of Shares And Warrants; Stock Down](https://longbridge.com/en/news/278896600.md)